Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer
Ali Ameri, Bahareh Tavakoli‐Far, Maryam Rostami, Bahman Abedi Kiasari, Delaram Sakhaei, Omar Ahmed, Fatemeh Forouzani, Yasaman Fazli
Topics & Concepts
AtezolizumabMedicineBreast cancerTriple-negative breast cancerOncologyImmunotherapyCancerMetastatic breast cancerImmune checkpointTargeted therapyInternal medicineBlockadeContext (archaeology)Cancer researchNivolumabReceptorBiologyPaleontologyCancer Immunotherapy and BiomarkersPeptidase Inhibition and AnalysisAdvanced Breast Cancer Therapies